Visit us at Booth #3684 in the BIO Exhibit Hall
McDonnell Boehnen Hulbert & Berghoff LLP was an exhibitor at the 2013 BIO International Convention in Chicago on April 22-25. During BIO, we networked with colleagues from around the world at our booth and convention sessions, hosted a reception at Fado Irish Pub and proud sponsor of the North Carolina Pavilion. Thank you to all who helped make BIO a success and we look forward to seeing you at BIO 2014!
You can check out the rest of our photos from BIO here: https://www.facebook.com/media/set/?set=a.733081566721423.1073741827.205110176185234&type=3
Billed as the largest global event for the biotechnology industry, 2013 BIO is organized by the Biotechnology Industry Organization. The organization represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
2013 BIO covered the wide spectrum of life science innovations and application areas. Drug discovery, biomanufacturing, genomics, biofuels, nanotechnology, and cell therapy are just a few of the industries represented at the BIO International Convention. It is estimated more than 15,000 leaders from over 65 countries attended 2013 BIO. The key elements of the event were education, networking, partnering and the 1,800 companies showcasing the latest technologies, products and services in the BIO Exhibition. View complete details at http://convention.bio.org/.
We are looking forward to hearing discussions at 2013 BIO about what is next for Association for Molecular Pathology v. Myriad Genetics, Inc. (the Myriad case). Ahead of the U.S. Supreme Court oral arguments hearing on April 15 and BIO 2013, read up on the latest developments in the following recent Patent Docs postings authored by MBHB partner Dr. Kevin Noonan entitled:
Is Lack of Preemption the Key for the Supreme Court to Decide in Myriad’s Favor?
Myriad Sets Forth Its Case to the Supreme Court